Benzinga · Sep 10, 2026
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415
Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $407 to $415.
ON
NASDAQ · ONC
BeOne Medicines Ltd.
Healthcare · Medical - Pharmaceuticals
$346.50
Down-$7.33 (-2.07%)
Updated Sep 16, 2026, 11:47 AM
SID Score
5.9/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 34.25B
- P/E ratio
- -21.14
- Dividend yield
- 0.00%
- 52-week range
- $253.95 – $385.22
- Volume
- 257.3K
- Avg. volume
- 259.1K
Price performance
ONC price history
1M range · 20 trading sessions · Daily adjusted prices
ONC closed at $346.50 after 20 trading sessions, down 6.14% for the selected period.
- Last close
- $346.50
- Period change
- -6.14%
- Period low
- $341.80
- Period high
- $376.86
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $353.55 | $354.50 | $345.80 | $346.50 | 257.3K |
| Sep 14, 2026 | $354.44 | $356.00 | $351.915 | $353.83 | 251.18K |
| Sep 11, 2026 | $345.11 | $349.08 | $341.22 | $346.51 | 307.78K |
| Sep 10, 2026 | $341.56 | $345.60 | $336.95 | $341.80 | 1M |
| Sep 9, 2026 | $347.82 | $351.94 | $346.17 | $351.00 | 674.73K |
| Sep 8, 2026 | $351.25 | $352.00 | $344.01 | $351.48 | 398.53K |
| Sep 4, 2026 | $359.71 | $362.67 | $357.58 | $358.26 | 202.36K |
| Sep 3, 2026 | $361.61 | $364.61 | $357.79 | $362.68 | 123.62K |
| Sep 2, 2026 | $364.99 | $370.48 | $360.53 | $361.78 | 295.2K |
| Sep 1, 2026 | $351.73 | $360.21 | $351.405 | $358.655 | 351.28K |
| Aug 31, 2026 | $356.50 | $361.03 | $352.86 | $359.58 | 346.05K |
| Aug 28, 2026 | $369.13 | $372.00 | $364.73 | $366.73 | 341.59K |
| Aug 27, 2026 | $372.35 | $374.94 | $371.51 | $372.49 | 225.07K |
| Aug 26, 2026 | $376.27 | $377.66 | $372.01 | $375.80 | 125.83K |
| Aug 25, 2026 | $370.12 | $380.00 | $369.49 | $376.37 | 396.29K |
| Aug 24, 2026 | $369.53 | $372.825 | $365.14 | $371.98 | 351.54K |
| Aug 21, 2026 | $375.00 | $379.48 | $374.37 | $374.47 | 252.6K |
| Aug 20, 2026 | $372.55 | $376.00 | $368.82 | $369.16 | 311.75K |
| Aug 19, 2026 | $371.56 | $379.20 | $371.05 | $376.86 | 379.9K |
| Aug 18, 2026 | $364.00 | $370.80 | $361.1401 | $369.15 | 613.55K |
Latest ONC news
The latest Smart Investors Daily articles mentioning ONC.
Stock researchCompany · Overview
ONC research
Overview
Company profile and research snapshot.
Company profile
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $397.00
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Sep 5, 2026
BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run
BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher share price leave investors weighing a strong track record against a less clear-cut value case. BeOne Medicines is up 86.0% over three years, which makes the stock more dependent on whether the business can now justify that stronger share price profile. FDA...
Yahoo · Sep 5, 2026
The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal
BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology drugs while investing more than US$1.00 billion in U.S. manufacturing. This combination of first-in-class immunotherapy approval and U.S. tariff exemption tied to onshoring commitments reshapes BeOne’s positioning in cancer care and its cost base in a key...
Yahoo · Sep 4, 2026
BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?
BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agreement gives BeOne Medicines AG (NASDAQ:ONC) an exemption from Section 232 pharmaceutical tariffs while recognizing more than $1 billion of U.S. manufacturing investment, including a $300 […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
